Closed-ended, linear, duplex adenoassociated virus dna, and uses thereof
AssigneeThe USA, as represented by the Secretary, Dept. of Health and Human Services
InventorsLina LI, Robert KOTIN
Life of this patent
Estimating the term…
Abstract
Closed-ended, linear, duplex (CELID) DNA molecules, recombinant AAV (rAAV), particles comprising CELID DNA, methods of making such molecules and particles, and therapeutic applications of such particles.
Claims21
A method of producing a recombinant AAV (rAAV) particle comprising heterologous DNA, the method comprising culturing a cell comprising:
- i) closed ended, linear duplex (CELiD) DNA comprising the heterologous DNA;
- and,
- ii) one or more nucleic acid molecules encoding one or more AAV capsid (Cap) proteins;
- under conditions suitable for formation of AAV particles containing the CELID DNA.
(canceled)
A recombinant AAV (rAAV) particle comprising heterologous DNA, wherein non-AAV vector DNA makes up less than 10% of the total amount of DNA in the particle.
A method of producing closed ended, linear duplex (CELiD) DNA, comprising heterologous DNA, the method comprising:
- a) culturing a cell comprising:
- i) one or more polynucleotide sequences encoding one or more adeno-associated virus (AAV) Rep proteins;
- and,
- ii) a nucleic acid molecule comprising heterologous DNA flanked by a pair of inverted terminal repeats (ITRs), wherein at least one ITR comprises an AAV Rep protein binding site and a AAV terminal resolution site (trs), and wherein at least one ITR can be used as an origin of replication;
- under conditions suitable for replication of the nucleic acid molecule, thereby producing new CELiD DNA molecules;
- and
- b) isolating the newly produced CELiD DNA molecules from the cell.
Dependencies are inferred from the claim text.